{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:01:00Z","timestamp":1792591260197,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019145","name":"Boston Biomedical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001340","name":"W. W. Smith Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016255","name":"INOVIO Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omto.2022.07.003","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T13:38:09Z","timestamp":1657114689000},"page":"289-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["In\u00a0vivo DNA-launched bispecific T\u00a0cell engager targeting IL-13R\u03b12 controls tumor growth in an animal model of glioblastoma multiforme"],"prefix":"10.1016","volume":"26","author":[{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devivasha","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Cassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.07.003_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13Ra2-targeted chimeric antigen receptor T\u00a0cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.07.003_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2022.07.003_bib3","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/neuonc\/nou166","article-title":"Beating the odds: extreme long-term survival with glioblastoma","volume":"16","author":"Bi","year":"2014","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib6","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.07.003_bib7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omto.2022.07.003_bib8","doi-asserted-by":"crossref","first-page":"126086","DOI":"10.1172\/jci.insight.126086","article-title":"DNA-encoded bispecific T\u00a0cell engagers and antibodies present long-term antitumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2022.07.003_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11882-007-0051-x","article-title":"IL-13 receptor isoforms: breaking through the complexity","volume":"7","author":"Tabata","year":"2007","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.omto.2022.07.003_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omto.2022.07.003_bib11","doi-asserted-by":"crossref","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"Plos One"},{"key":"10.1016\/j.omto.2022.07.003_bib12","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-11-1669","article-title":"Stem-like tumor initiating cells isolated from IL13R\u03b12-expressing gliomas are targeted and killed by IL13-zetakine redirected T\u00a0cells","volume":"18","author":"Brown","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/sj.neo.7900234","article-title":"IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13","volume":"4","author":"Mintz","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.omto.2022.07.003_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib15","first-page":"481","article-title":"Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme","volume":"15","author":"Debinski","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib16","doi-asserted-by":"crossref","first-page":"42997","DOI":"10.18632\/oncotarget.17792","article-title":"IL13RA2 targeted alpha particle therapy against glioblastomas","volume":"8","author":"Sattiraju","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.07.003_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/14653249.2012.666633","article-title":"Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor a 2 chain in recurrent malignant glioma patients with HLA-A \u2217 24\/A \u2217 02 allele","volume":"14","author":"Iwami","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omto.2022.07.003_bib18","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","volume":"32","author":"Pollack","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13Ra2 humanized scFv-based CAR T\u00a0cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2022.07.003_bib20","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2022.07.003_bib21","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T\u00a0cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","article-title":"Adoptive transfer of IL13Ra2-specific chimeric antigen receptor T\u00a0cells creates a pro-inflammatory environment in glioblastoma","volume":"26","author":"Pituch","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.07.003_bib23","series-title":"RYBREVANT\u2122 (Amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","author":"Janssen","year":"2021"},{"key":"10.1016\/j.omto.2022.07.003_bib24","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C","article-title":"Optimizing anti-CD3 affinity for effective T\u00a0celltargeting against tumor cells","volume":"32","author":"Bortoletto","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omto.2022.07.003_bib25","doi-asserted-by":"crossref","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","author":"Haber","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2022.07.003_bib26","doi-asserted-by":"crossref","first-page":"e002444","DOI":"10.1136\/jitc-2021-002444","article-title":"Dichotomous impact of affinity on the function of T\u00a0cell engaging bispecific antibodies","volume":"9","author":"Poussin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2022.07.003_bib27","doi-asserted-by":"crossref","first-page":"133757","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2022.07.003_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18632\/oncotarget.26535","article-title":"Simplifying checkpoint inhibitor delivery through in\u00a0vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)","volume":"10","author":"Perales-Puchalt","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.07.003_bib29","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-18-1429","article-title":"Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in\u00a0vivo","volume":"78","author":"Duperret","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib30","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.celrep.2018.10.062","article-title":"In\u00a0vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model","volume":"25","author":"Patel","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omto.2022.07.003_bib31","first-page":"118","article-title":"Neural stem cells secreting bispecific T\u00a0cell engager to induce selective antiglioma activity","author":"Pituch","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.omto.2022.07.003_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-20-0508","article-title":"Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII","volume":"20","author":"Sternjak","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2022.07.003_bib33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T\u00a0cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.07.003_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2014-02-556340","article-title":"OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues","volume":"123","author":"Wunderlich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.07.003_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-050520-100526","article-title":"Humanized mouse models to evaluate cancer immunotherapeutics","volume":"5","author":"Guil-Luna","year":"2021","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.omto.2022.07.003_bib36","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/cmi.2017.106","article-title":"Human PBMC-transferred murine MHC class I\/II-deficient NOG mice enable long-term evaluation of human immune responses","volume":"15","author":"Yaguchi","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omto.2022.07.003_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MPH.0b013e3181468c68","article-title":"Medulloblastomas expressing IL13R\u03b12 are targets for IL13-zetakine+ cytolytic T\u00a0cells","volume":"29","author":"Stastny","year":"2007","journal-title":"J.\u00a0Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omto.2022.07.003_bib38","first-page":"6381","article-title":"Interleukin-13 receptor \u03b12 chain in human head and neck cancer serves as a unique diagnostic marker","volume":"9","author":"Kawakami","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib39","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.22134","article-title":"Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy","volume":"107","author":"Kioi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.omto.2022.07.003_bib40","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-13-1253","article-title":"Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy","volume":"19","author":"Beard","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.07.003_bib41","doi-asserted-by":"crossref","first-page":"e0130980","DOI":"10.1371\/journal.pone.0130980","article-title":"Role of IL13RA2 in sunitinib resistance in clear cell renal cell carcinoma","volume":"10","author":"Shibasaki","year":"2015","journal-title":"Plos One"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:25:52Z","timestamp":1762496752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522000924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"alternative-id":["S2372770522000924"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.07.003","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo DNA-launched bispecific T\u00a0cell engager targeting IL-13R\u03b12 controls tumor growth in an animal model of glioblastoma multiforme","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}